drugset
drugset / Trial / NCT01007448

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

NCT01007448 ↗

Phase 4 Completed 59 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.

Timeline

Start
2010-01-06
Primary completion
2014-02-20
Completion
2014-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexarotene Small molecule 150 mg/m2 Oral
Subject Bexarotene Small molecule 300 mg/m2 Oral

Indications

primary cutaneous T-cell lymphoma